Table 2.

Univariate analysis of factors affecting PFS.

Factors	PFS (months)	HR	95% CI	p
Age
<50 (n = 21)	2	0.75	0.39–1.42	0.372
≥50 (n = 23)	2.1
Endocrine partner
Anti-estrogens (n = 5)	2	0.94	0.69–1.28	0.679
Letrozole or anastrozole (n = 8)	2.1
Exemestane (n = 19)	1.9
Fulvestrant (n-10)	2
Medroxyprogesterone (n = 2)	2
Liver metastasis
No (n = 19)	2	1.11	0.60–2.06	0.732
Yes (n = 25)	2
Lung metastasis
No (n = 20)	2	1.03	0.56–1.91	0.916
Yes (n = 24)	2
Visceral metastasis
No (n = 10)	1.9	0.81	0.38–1.71	0.583
Yes (n = 34)	2
Number of metastatic sites
1 (n = 6)	4.1	2.79	1.09–7.92	0.035
≥2 (n = 38)	2
Chemotherapy lines for MBC
≤2 (n = 25)	2.1	1.99	1.03–3.84	0.039
≥3 (n = 19)	2
Menopausal status
Premenopausal (n = 21)	2	0.99	0.54–1.83	0.981
Postmenopausal (n = 23)	2
Endocrine sensitivity
No (n = 5)	1.8	0.39	0.15–1.04	0.061
Yes (n = 39)	2.1
Benefits of CDK4/6i
No benefits (n = 17)	2	0.66	0.35–1.23	0.187
Benefits (n = 27)	2.1
DFS
≤24 months (n = 21)	2	0.78	0.42–1.44	0.426
>24 months (n = 23)	2.1
Number of therapy between tucidinostat and CDK4/6i
0 (n = 7)	4.5	3.96	1.48–10.61	0.006
≥1 (n = 37)	2
Number of tucidinostat treatment
≤3 (n = 7)	4.5	2.55	1.08–6.62	0.037
≥3 (n = 37)	2